Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Congress ponders whether AI should have the power of the patent - Roll Call

Lawmakers are beginning to consider ways in which artificial intelligence is involved in inventive processes like discovery of new drugs.

Roll Call

Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions

Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

The Guardian - UK

Doctor with Stage 4 cancer is refused access to lifesaving treatment on the NHS

Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Over dinner in Davos, the CEOs of Novartis, Coca-Cola, and Grab shared what’s worrying them

Highlights from Fortune's dinner in Davos.

Fortune

Coca-Cola and Novartis's CEOs don't care if 'ESG' has become a toxic phrase among some

It's about delivering on corporate missions in a sustainable way, they said at Davos.

Fortune

1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

StockNews.com

I can’t get my HRT, again – this second UK shortage wasn’t supposed to happen

The government claims that supply issues have been tackled, but menopausal women know this is far from the truth, says author Rose George

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Pharma's expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially…

The Conversation

Gene drug ‘only hope’ for Turkish child, but costs millions

Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.

Al Jazeera

Queensland researchers find immune-boosting drug could lessen COVID-19 severity if antivirals fade

Unlike antiviral treatments, researchers say the experimental medication would not attack the virus that causes COVID-19, but target the immune system instead.

ABC News

Development-supporting new wildlife habitat completes as tragic tale unearthed behind Humber Bank site

Novartis Ings 'opens' bringing pleasure at peaceful use to surviving relatives of German bomb blast

Birmingham Post

Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14

Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing

Benzinga

Pharmaceutical giant Novartis to cut 400 Dublin jobs

Employees were informed of the phased cuts earlier today

Dublin Live

Pollen does more than make you sneeze. It can cause thunderstorm asthma, even if you're not asthmatic

Climate change has caused melting icebergs, flooding, and landslides. It can also bring about an increase in pollen levels, prolong the duration of pollen season, and cause more pollen-related health problems.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novartis Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Novartis. Looking at options history for Novartis (NYSE:NVS) we detected 21 strange trades.

Benzinga

Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..

Reuters

Birmingham Post

'Motorway service station' for migrating birds will put Humber in economic development fast lane

Novartis Ings is taking shape after legacy gift from pharmaceutical giant

Benzinga

Benzinga Before The Bell: Twitter Whistleblower Peiter Zatko To Depose Before Senate Panel, GameStop To Boost Employee Compensation To Drive Growth, California Proposes Total Ban On New Gasoline Car Sales By 2035 And Other Top Financial Stories Thursday, August 25

Reuters Stuck By Chip Shortage, Stellantis Halts Production In Sochaux Plant

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Birmingham Post

Former Tioxide site relaunched as a major industrial location by ABP as Rolls-Royce shortlisting secured

Sprawling Humber bank location opened up as part of major land release by port operator

The Hindu

India’s patent law safeguards under fire

The new recommendation reduces the period within which patent applications can be challenged to six months

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis The company currently is not generating any sale, with most of its products in early stages of development By Tina Yip

1 … 3 4 5 6

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.